How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Shuanghuanglian (SHL) Injection Market
- By Product Formulation: Standard SHL Injection, Enhanced SHL Injection with Additional Herbal Extracts, SHL Injection with Antiviral Additives
- By Indication: Respiratory Tract Infections, Influenza Treatment, Upper Respiratory Inflammation, Bronchitis, Common Cold
- By End User: Hospitals, Clinics, Traditional Chinese Medicine Centers, Community Health Centers
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Sales to Healthcare Institutions
- By Dosage Strength: 5ml Vials, 10ml Vials, 20ml Vials
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Standard SHL Injection leads By Product Formulation at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Shuanghuanglian (SHL) Injection Market report
A complete, evidence-based study - 12 chapters and 117 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Product Formulation 3
Indication 5
End User 4
Distribution Channel 4
Dosage Strength 3
Companies profiled
Shandong Buchang Pharmaceuticals Co. Ltd.
Harbin Pharmaceutical Group Co. Ltd. (Hayao)
China National Pharmaceutical Group Corporation (Sinopharm)
Jiangsu Kanion Pharmaceutical Co. Ltd.
Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.
Shenzhen Salubris Pharmaceuticals Co. Ltd.
Hubei Biocause Pharmaceutical Co. Ltd.
Zhejiang Hisun Pharmaceutical Co. Ltd.
Sichuan Kelun Pharmaceutical Co. Ltd.
Shanghai Pharmaceuticals Holding Co. Ltd.
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Shandong Buchang Pharmaceuticals Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Harbin Pharmaceutical Group Co. Ltd. (Hayao)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →China National Pharmaceutical Group Corporation (Sinopharm)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Jiangsu Kanion Pharmaceutical Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Hubei Biocause Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Zhejiang Hisun Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sichuan Kelun Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Shanghai Pharmaceuticals Holding Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,973M by 2033 · 11.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Standard SHL Injection63.3
- Enhanced SHL Injection with Additional Herbal Extracts18.3
- SHL Injection with Antiviral Additives18.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$998.6M → $2,258M · 10.7%
Europe$696.0M → $1,628M · 11.2%
Asia Pacific$635.5M → $1,391M · 10.3%
Latin America$393.4M → $915.4M · 11.1%
Middle East and Africa$302.6M → $714.7M · 11.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.952026
10.962027
10.972028
10.992029
11.002030
11.012031
11.032032
11.042033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Shandong Buchang Pharmaceuticals Co. Ltd.10.1
- Harbin Pharmaceutical Group Co. Ltd. (Hayao)14.1
- China National Pharmaceutical Group Corporation (Sinopharm)7.6
- Jiangsu Kanion Pharmaceutical Co. Ltd.11.7
- Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.13.1
- Shenzhen Salubris Pharmaceuticals Co. Ltd.15.3
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Formulation22.0%
Indication24.0%
End User14.8%
Distribution Channel28.8%
Dosage Strength10.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.7
- Europe23.6
- Asia Pacific20.1
- Latin America13.3
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Shandong Buchang Pharmaceuticals Co. Ltd. | 95 | 83 | 97 | 75 | 88 | 78 | 86 |
| Harbin Pharmaceutical Group Co. Ltd. (Hayao) | 72 | 91 | 91 | 80 | 80 | 85 | 83 |
| China National Pharmaceutical Group Corporation (Sinopharm) | 70 | 73 | 87 | 78 | 69 | 69 | 74 |
| Jiangsu Kanion Pharmaceutical Co. Ltd. | 68 | 72 | 82 | 79 | 63 | 64 | 71 |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 56 | 59 | 55 | 54 | 76 | 71 | 62 |
| Shenzhen Salubris Pharmaceuticals Co. Ltd. | 63 | 47 | 52 | 52 | 49 | 65 | 55 |
| Hubei Biocause Pharmaceutical Co. Ltd. | 60 | 57 | 65 | 64 | 55 | 64 | 61 |
| Zhejiang Hisun Pharmaceutical Co. Ltd. | 50 | 55 | 44 | 45 | 45 | 49 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Shandong Buchang Pharmaceuticals Co. Ltd.
- Harbin Pharmaceutical Group Co. Ltd. (Hayao)
- China National Pharmaceutical Group Corporation (Sinopharm)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Shandong Buchang Pharmaceuticals Co. Ltd. | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Harbin Pharmaceutical Group Co. Ltd. (Hayao) | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| China National Pharmaceutical Group Corporation (Sinopharm) | − | ✓ | ◐ | ✓ | ✓ | ✓ |
| Jiangsu Kanion Pharmaceutical Co. Ltd. | ✓ | ◐ | ◐ | ◐ | − | − |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | − | − | − | ◐ | ◐ | ◐ |
| Shenzhen Salubris Pharmaceuticals Co. Ltd. | ◐ | − | − | ◐ | − | − |
| Hubei Biocause Pharmaceutical Co. Ltd. | − | − | − | ◐ | ◐ | ◐ |
| Zhejiang Hisun Pharmaceutical Co. Ltd. | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Shandong Buchang Pharmaceuticals Co. Ltd.86
2Harbin Pharmaceutical Group Co. Ltd. (Hayao)83
3China National Pharmaceutical Group Corporation (Sinopharm)74
4Jiangsu Kanion Pharmaceutical Co. Ltd.71
5Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.62
6Hubei Biocause Pharmaceutical Co. Ltd.61
7Shenzhen Salubris Pharmaceuticals Co. Ltd.55
8Zhejiang Hisun Pharmaceutical Co. Ltd.48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Shandong Buchang Pharmaceuticals Co. Ltd.Harbin Pharmaceutical Group Co. Ltd. (Hayao)
Challenger2
Strong scale, closing on the leaders.
China National Pharmaceutical Group Corporation (Sinopharm)Jiangsu Kanion Pharmaceutical Co. Ltd.
Contender2
Focused players with pockets of strength.
Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.Hubei Biocause Pharmaceutical Co. Ltd.
Niche2
Specialists in a single segment or region.
Shenzhen Salubris Pharmaceuticals Co. Ltd.Zhejiang Hisun Pharmaceutical Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Formulation in North America, then scale across Shuanghuanglian (SHL) Injection Market — a $347M beachhead inside a $4.80B market.
Beachhead (SOM)$347Mobtainable near-term
Serviceable (SAM)$1.91Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Standard SHL Injection
Best fit — highest urgency & budget in Product Formulation.
Economic buyer76 fit
Enhanced SHL Injection with Additional Herbal Extracts
Strong fit — clear ROI and a fast path to value.
End user69 fit
SHL Injection with Antiviral Additives
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Formulation in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel26%
Digital / self-serve19%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Product Formulation leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Shuanghuanglian (SHL) Injection Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified25%
Evaluation15%
Closed-won6%
$14.1KCAC
$79KLTV
5.6:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Shuanghuanglian (SHL) Injection Market is a resilient opportunity — $7.63B by 2033, compounding at 4.4%.
TAM · 2025$5.42Btoday
TAM · 2033$7.63Bforecast
CAGR4.4%2027–2033
Cumulative$58.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.63BTotal addressable market
SAM$2.99BServiceable available market
SOM$623MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.4% CAGR
Demand compounds through 2033, outpacing GDP across Product Formulation.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Formulation moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.63BLarge & growingTAM by 2033 at 4.4% CAGR
$2.99BServiceable nowreachable with today’s model
$623MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.96BBear2.8% CAGR
$7.63BBase4.4% CAGR
$9.77BBull5.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Shuanghuanglian (SHL) Injection Market — a $6.20B market by 2033. Plan: grow share from 7.2% to 14.8%.
Market size · 2033$6.20Btotal addressable
Market CAGR6.2%2027–2033
Target share14.8%from 7.2% today
Revenue ambition$918Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.2% | 14.8% | At risk |
| Revenue | $444M | $918M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 33.5% | 39.9% | Behind |
| Customer retention | 90.0% | 93.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Formulation
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Indication capability
A defensible second engine — invest in Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Formulation share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $109M capacity & capability investment
- Greenlight bolt-on M&A in Indication
- Authorise North America expansion plan
- Fund R&D program for Product Formulation leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Shuanghuanglian (SHL) Injection Market conversation — a $7.72B market you can size, segment and defend in minutes.
Market size · 2033$7.72Btotal opportunity
Growth9.9%CAGR to 2033
Addressable buyers1,331+accounts in scope
Typical ROI6.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Formulation
Goal Grow share in Product Formulation
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.7×return on cost, year one
< 2 mopayback period
$71K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Shandong Buchang Pharmaceuticals Co. Ltd.Harbin Pharmaceutical Group Co. Ltd. (Hayao)China National Pharmaceutical Group Corporation (Sinopharm)Jiangsu Kanion Pharmaceutical Co. Ltd.Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.Shenzhen Salubris Pharmaceuticals Co. Ltd.Hubei Biocause Pharmaceutical Co. Ltd.Zhejiang Hisun Pharmaceutical Co. Ltd.+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Shuanghuanglian (SHL) Injection Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Shuanghuanglian (SHL) Injection Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Shuanghuanglian Oral Liquid Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportShuanghuanglian Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportShuanghuanglian Capsule Market
Market size, share, segmentation and regional forecast.
$486M market · 2025 base year
View reportShower Toilet Chair Market
Market size, share, segmentation and regional forecast.
$828M market · 2025 base year
View reportShower Seats Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportShower Lift Chair Market
Market size, share, segmentation and regional forecast.
$426M market · 2025 base year
View reportShoulder Temporary Spacer Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportShoulder Shower Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportShoulder Replacement Devices Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportShoulder Orthosis System Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportShoulder Neck Massage Instrument Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportShoulder Microwave Heating Pad Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.